Insight Molecular Diagnostics Inc. Marketable Securities, Realized Gain (Loss), Excluding Other-than-temporary Impairment Loss
Insight Molecular Diagnostics Inc. (IMDX) reported Marketable Securities, Realized Gain (Loss), Excluding Other-than-temporary Impairment Loss of $1.40 million for the 3-month period ending 2023-12-31, per its 10-K filed 2025-03-24.
Financial Statements › Income Statement › Other Income
us-gaap:MarketableSecuritiesRealizedGainLossExcludingOtherThanTemporaryImpairments · last filed 2025-03-24
- Insight Molecular Diagnostics Inc. marketable securities, realized gain (loss), excluding other-than-temporary impairment loss for the quarter ending 2023-12-31 was $1.40M.
| Period end | Marketable Securities, Realized Gain (Loss), Excluding Other-than-temporary Impairment Loss 3 month |
|---|---|
| 2023-12-31 | $1.40M 10-K · filed 2025-03-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| IMMUCELL CORP /DE/ (ICCC) | United States | $0.091B | 116.10 |
| BIOMERICA INC (BMRA) | United States | $0.011B | |
| Q/C TECHNOLOGIES, INC. (QCLS) | United States | $0.008B | -1.93 |
| Cardio Diagnostics Holdings, Inc. (CDIO) | United States | $0.006B | |
| VOLITIONRX LTD (VNRX) | $0.003B | -0.64 | |
| MYRIAD GENETICS INC (MYGN) | United States | $0.397B | -4.84 |
| Alpha Teknova, Inc. (TKNO) | United States | $0.500B | -18.12 |
| QuidelOrtho Corp (QDEL) | United States | $0.733B | -0.90 |
| ACHIEVE LIFE SCIENCES, INC. (ACHV) | United States | $0.806B | -5.88 |
| Intellia Therapeutics, Inc. (NTLA) | United States | $1.705B | -5.92 |